Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

B-RAF is the most frequently mutated protein kinase in human cancers.1 The finding that oncogenic mutations in BRAF are common in melanoma2 followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway3 offered hope that inhibition of B-RAF kinase activity could benefit me...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Bollag, Gideon, Hirth, Peter, Tsai, James, Zhang, Jiazhong, Ibrahim, Prabha N., Cho, Hanna, Spevak, Wayne, Zhang, Chao, Zhang, Ying, Habets, Gaston, Burton, Elizabeth A., Wong, Bernice, Tsang, Garson, West, Brian L., Powell, Ben, Shellooe, Rafe, Marimuthu, Adhirai, Nguyen, Hoa, Zhang, Kam Y. J., Artis, Dean R., Schlessinger, Joseph, Su, Fei, Higgins, Brian, Iyer, Raman, D'Andrea, Kurt, Koehler, Astrid, Stumm, Michael, Lin, Paul S., Lee, Richard J., Grippo, Joseph, Puzanov, Igor, Kim, Kevin B., Ribas, Antoni, McArthur, Grant A., Sosman, Jeffrey A., Chapman, Paul B., Flaherty, Keith T., Xu, Xiaowei, Nathanson, Katherine L., Nolop, Keith
Format: Artigo
Język:Inglês
Wydane: 2010
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2948082/
https://ncbi.nlm.nih.gov/pubmed/20823850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09454
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy